AI Stock Memo: KTTA - Pasithea Therapeutics - RankAlpha

KTTA

Rating neutralTentativeAI Memo

Pasithea Therapeutics

As of 2026-04-15/Confidence low/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

low

Horizon

6‑12m

Key catalyst

Nasdaq bid-price cure decision remains the clearest near-term stock event • 2026-08-19

Expected move: +8%

Biggest risk

This is still a low-coverage, single-lead, clinical-stage biotech with no commercial revenue, continuing losses, and meaningful execution risk. The Nasdaq minimum-bid notice is a live overhang, and any weak data, enrollment slippage, or forced reverse split could outweigh the cash-runway benefit [#8-K-2026-02-20] [#10-K-2026-03-30].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Primary-source support is real but narrow: the 10-K shows $55.2 million of cash at December 31, 2025 with management expecting runway into at least the first half of 2028, while PAS-004 has ongoing cancer and NF1 studies with additional interim data planned through 2026 [#10-K-2026-03-30]. If the company posts credible clinical progress and resolves Nasdaq compliance without heavy damage, the stock has room to re-rate from a depressed base.

Research note

Recommendation

neutral

Confidence

low

As of

2026-04-15

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

PAS-004 advanced cancer updates are expected through 2026
Adult NF1 Part A completion is a 2026 execution checkpoint
Primary-source support is real but narrow: the 10-K shows $55.2 million of cash at December 31, 2025 with management expecting runway into at least the first half of 2028, while PAS-004 has ongoing cancer and NF1 studies with additional interim data planned through 2026 [#10-K-2026-03-30].

BearKey bullets

Despite runway guidance into at least 1H28, the company says it will require additional capital for full development and commercialization, so dilution risk is deferred rather than removed.
KTTA is effectively a concentrated single-platform story after ceasing further PAS-003 development in 2025, increasing asset-specific downside if PAS-004 slips.
Nasdaq bid-price non-compliance could end in reverse split, extension friction, or delisting pressure.

WatchKey bullets

Nasdaq bid-price cure decision remains the clearest near-term stock event

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $1 (p=45%)

Bull/Bear spread: +101% / -57%

Vs latest close: Bull +101% · Base +8% · Bear -57%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

Primary-source evidence supports a cautious monitoring stance rather than an aggressive bullish call. The 10-K provides real clinical and balance-sheet anchors, but forward visibility is still limited to early-stage execution milestones and management-planned interim updates, while the February 2026 Nasdaq notice adds a nearer-term technical overhang [#10-K-2026-03-30] [#8-K-2026-02-20]. The peer set remains provisional and mostly market-cap based, so the thesis should be treated as tentative optionality backed by cash rather than a peer-validated rerating setup.

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

PAS-004 advanced cancer updates are expected through 2026
Adult NF1 Part A completion is a 2026 execution checkpoint

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Price $1 as of 2026-05-28

Nearest Scenario: Base (∆ 8%)

Targets vs latest close: Bull +101% · Base +8% · Bear -57%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-19
Nasdaq bid-price cure decision remains the clearest near-term stock event
KTTA disclosed on February 20, 2026 that Nasdaq notified the company it was below the $1.00 minimum bid requirement and gave it until August 19, 2026 to regain compliance; failure to cure can push the company toward a reverse split, an extension request, or delisting proceedings, making this the highest-visibility near-term equity catalyst [#8-K-2026-02-20].
Prob 80.00% • Move -30.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

PAS-004 advanced cancer updates are expected through 2026
2026-12-31
The 2025 10-K says Pasithea has completed dose escalation through cohort 8 in the first-in-human advanced cancer study, has not reached MTD, has seen no DLTs in assessed cohorts, and plans to provide additional interim data throughout 2026; positive PK, tolerability, or early efficacy signals could help sentiment, but the program remains early and data risk is high [#10-K-2026-03-30].
Prob 60% • Move 45% • Priced-in 25%
Adult NF1 Part A completion is a 2026 execution checkpoint
2026-12-31
The 2025 10-K says Pasithea initiated the Phase 1/1b adult NF1 trial in May 2025, dosed the first patient in July 2025, has enrolled and dosed three patients in each of the initial four Part A cohorts, and expects to complete Part A by the end of 2026 before moving to Part B in 2027 following FDA dialogue; clean execution would support the platform narrative, while slippage would reinforce a monitoring-only view [#10-K-2026-03-30].
Prob 55% • Move 35% • Priced-in 20%

Risks

Despite runway guidance into at least 1H28, the company says it will require additional capital for full development and commercialization, so dilution risk is deferred rather than removed.
KTTA is effectively a concentrated single-platform story after ceasing further PAS-003 development in 2025, increasing asset-specific downside if PAS-004 slips.
Nasdaq bid-price non-compliance could end in reverse split, extension friction, or delisting pressure.
PAS-004 is early-stage and any safety, efficacy, enrollment, or regulatory setback could materially impair equity value.

Peers

Symbol	Summary
NRSN	Small-cap biotech candidate from the packet with similar sector and market-cap range; this is only a loose comparator for early-stage development risk and financing sensitivity, not a validated same-indication operating peer.
BOLD	Another packet-supplied small-cap biotech candidate near KTTA's market-cap range; it is best treated as a market-cap and capital-markets comp, with limited value for program-level read-through.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-04-15